IP Library › Granted Patent US 7,378,389
Granted Patent B2
US 7,378,389 · App. 11/752,096 · Granted May 27, 2008

Botulinum toxin neurotoxic component for treating juvenile cerebral palsy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,378,389
App. No.
11/752,096
Granted
May 27, 2008
Kind
B2
Abstract

The invention provides for the use of a presynaptic neurotoxin (for example a bacterial neurotoxin such as botulinum toxin A) for the manufacture of a medicament for the treatment of cerebral palsy in juvenile patients. The juvenile patients are preferably juveniles of up to 6 years in age.

Claims (6)

1. A method for treating cerebral palsy in a juvenile patient, the method comprising the step of administering to the patient a therapeutically effective amount of the neurotoxic component of a botulinum toxin, wherein the neurotoxic component administered to the patient has been purified from a botulinum toxin obtained by fermenting a Clostridium botulinum , wherein the botulinum toxin is a botulinum toxin type A.

2. A method for treating cerebral palsy in a juvenile patient, the method comprising the step of administering to the patient a therapeutically effective amount of the neurotoxic component of a single botulinum toxin type, wherein the neurotoxic component administered to the patient has been purified from a single botulinum toxin type obtained by fermenting a Clostridium botulinum , wherein the botulinum toxin is a botulinum toxin type A.

3. A method for treating cerebral palsy in a juvenile patient, the method comprising the step of administering to the patient a therapeutically effective amount of the neurotoxic component of only a botulinum toxin type A, wherein the neurotoxic component administered to the patient has been purified from a botulinum toxin type A obtained by fermenting a Clostridium botulinum.

4. The methods of claims 1 , 2 or 3 wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.

5. The methods of claims 1 , 2 or 3 wherein the botulinum toxin obtained by fermenting a Clostridium botulinum is a botulinum toxin complex.

6. The methods of claims 1 , 2 or 3 wherein the botulinum toxin obtained by fermenting a Clostridium botulinum is a botulinum toxin complex with a molecular weight of about 900 kilodaltons.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2007
From: MERZ PHARMA GMBH & CO. KGAA; MERZ PHARMACEUTICALS GMBH
To: ALLERGAN, INC.
Reel/Frame 019831/0865 →